656: Shareholder Meeting And Dividend Decision Will Drive Positive Momentum

Key Takeaways

• Expansion in healthcare, insurance, tourism, and branded consumer products, supported by rising emerging market wealth, enhances revenue growth and earnings diversification.
  
• Strategic focus on innovative health, digitalization, and portfolio optimization boosts profitability, operational efficiency, and financial stability.
  
• Sustained revenue declines, asset sales, high debt, and geopolitical risks threaten long-term earnings, operating scale, and stability amid rising competition and shifting sector conditions.

Catalysts

Operates in the health, happiness, wealth, and intelligent manufacturing sectors in Mainland China, Portugal, and internationally.

• Fosun's aggressive international expansion-particularly in healthcare (Fosun Pharma, Henlius), insurance (Fosun Insurance Portugal, Peak Re), tourism (FTG/Club Med), and branded consumer products (Shede, Yuyuan)-is supported by rising middle class and wealth in emerging markets and the increasing globalization of Chinese capital and brands, which is likely to drive both revenue growth and improved earnings diversification.
  
• The group's strong health segment momentum, underpinned by expanding innovative drug pipelines, rising overseas licensing revenues, and the growing elderly population's demand for pharmaceuticals and healthcare services, is set to fuel sustainable growth and higher net margins within its healthcare business.
  
• Continued investment in digitalization and full-scale AI adoption across insurance, health, and consumer businesses enhances operational efficiency, sharpens customer acquisition, and supports scalable earnings and margin expansion-strengthening long-term profitability prospects.
  
• Ongoing portfolio optimization via asset divestment and reallocation into higher-margin, asset-light sectors (such as insurance/wealth management, tourism, and innovative health) is expected to boost ROE, reduce leverage risk, and support more stable earnings and cash flows.
  
• The company's proactive deleveraging and reduction of financing costs (e.g., lowering average borrowing rates, expanded access to diversified credit channels) address key balance sheet concerns, improving net margins and providing greater financial flexibility for growth initiatives.

Fosun International Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Fosun International's revenue will grow by 4.5% annually over the next 3 years.
• Analysts assume that profit margins will increase from -13.5% today to 2.2% in 3 years time.
• Analysts expect earnings to reach CN¥4.4 billion (and earnings per share of CN¥0.52) by about July 2029, up from -CN¥23.4 billion today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 11.8x on those 2029 earnings, up from -1.3x today. This future PE is greater than the current PE for the HK Industrials industry at 7.1x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 13.03%, as per the Simply Wall St company report.

Risks

• Despite strong overseas growth, total revenue and health segment revenue both slightly decreased in the first half of 2025, with significant double-digit declines in the happiness (consumer) and intelligent manufacturing segments, suggesting persistent weakness in key business areas that could depress group revenue and overall earnings in the long term.
  
• Continued divestment of noncore and even some core assets to reduce leverage may dilute future revenue streams, limit operating scale, and constrain the group's ability to generate steady earnings, especially as asset disposals are required to maintain financial flexibility.
  
• Elevated debt levels and interest-bearing liabilities at the group's consolidated level have slightly rebounded, with management explicitly acknowledging ongoing refinancing needs, meaning the company remains sensitive to rising global interest rates or tightening credit conditions, which could squeeze net margins and heighten refinancing risk.
  
• Increased globalization-over 53% of revenue from overseas markets-raises exposure to deglobalization risk and geopolitical tensions, including potential regulatory scrutiny in cross-border M&A and outbound Chinese investments; these adverse trends could disrupt expansion plans, hinder international market access, and impact both revenue and profit growth.
  
• Intensifying competition and rapid technological disruption across core sectors (pharma, tourism, insurance) require continuous high R&D and capex, while simultaneous sector adjustments-such as the cooling China pharmaceutical market and pressured consumer spending-could result in asset misallocation, volatile returns, and ongoing margin pressure group-wide.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of HK$5.08 for Fosun International based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$5.7, and the most bearish reporting a price target of just HK$4.4.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CN¥198.2 billion, earnings will come to CN¥4.4 billion, and it would be trading on a PE ratio of 11.8x, assuming you use a discount rate of 13.0%.
• Given the current share price of HK$4.2, the analyst price target of HK$5.08 is 17.3% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.